Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Pepgen Inc

Clinical trials sponsored by Pepgen Inc, explained in plain language.

PepGen Inc PEPG NASDAQ

Biotechnology company developing peptide-conjugated oligonucleotide therapies for neuromuscular diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Completed 1 Terminated 1

New drug PGN-EDODM1 tested for muscle disease

Disease control Completed

This early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.

Phase: PHASE1 • Sponsor: PepGen Inc • Aim: Disease control

Last updated Jun 27, 2026 09:04 UTC